A patient under general anesthesia
Conditions
Interventions
Experimental group1:Induction phase: Administer remimazolam besylate 0.3 mg/kg IV bolus, with supplemental doses of 0.05 mg/kg as needed. Combine with sufentanil (0.2–0.4 µg/kg) and rocuronium (1 mg/k
Experimental group2:Induction: Remazolam 0.3 mg/kg is administered intravenously, with a 0.05 mg/kg dose added if necessary. Combined with sufentanil (0.2–0.4 µg/kg) and rocuronium bromide (1 mg/kg),
Experimental group3:Induction phase: Administer remimazolam besylate 0.3 mg/kg IV bolus, with supplemental doses of 0.05 mg/kg as needed. Combine with sufentanil (0.2–0.4 µg/kg) and rocuronium (1 mg/k
Sponsors
Suzhou Ninth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 18-65 years, with no gender restrictions; (2) Anesthesia Society of America (ASA) grade I to III; (3) Body mass index (BMI) between 18.5 and 30 kg/m²; (4) Scheduled for elective general anesthesia surgery with an estimated duration exceeding 30 minutes; (5) Participants voluntarily agree to participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Contraindications to general anesthesia or a history of adverse reactions to anesthesia; (2) Presence of traumatic brain injury, increased intracranial pressure, stroke, unstable angina, or myocardial infarction; (3) Respiratory insufficiency, obstructive pulmonary disease, difficult airway, or a modified Mallampati score of class III or IV; (4) Poorly controlled diabetes mellitus or hypertension; (5) History of drug abuse, alcoholism, or substance dependence; (6) Abuse or long-term use of analgesics, sedatives, or anesthetics; (7) Known or suspected allergy or contraindication to any component of the study drugs or related medications used in the procedures; (8) History of psychiatric disorders; (9) Participation in other clinical trials within 1 month prior to screening; (10) Pregnant or lactating women; women of childbearing potential and men who are unwilling to use effective contraception; (11) Any other condition deemed by the investigator to be inappropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anesthesia induction and maintenance success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total fentanyl dose;Frequency of use of vasoactive drugs during surgery;Time to open your eyes;Wake-up time;PACU residence time ;Length of hospital stay after surgery;Adverse reaction incidence; | — |
Countries
China
Contacts
Public ContactChao Zhang
Suzhou Ninth People's Hospital
Outcome results
None listed